In collaboration with leading cancer centers,
research results to be presented from 41 studies across 19
solid tumor types demonstrating Caris' impact on precision
medicine
IRVING,
Texas, May 14, 2024 /PRNewswire/ -- Caris Life
Sciences® (Caris), the leading next-generation AI
TechBio company and precision medicine pioneer, today announced
that the company and collaborators from the biopharma industry and
leading cancer centers, including those within the Caris Precision
Oncology Alliance™ (POA), will collectively present 41 studies
across 19 tumor types at the 2024 American Society of Clinical
Oncology (ASCO®) Annual Meeting May 31 to June 4, 2024 (Booth #28001). The
findings demonstrate the power of Caris' comprehensive multi-modal
database to enable novel insights into cancer that could have
profound effects on a patient's diagnosis, prognosis, care plan and
response to treatment.
The findings demonstrate the power of
Caris' comprehensive multi-modal database to enable novel insights
into cancer
"We are immensely proud of the collaborative studies accepted
for presentation at ASCO, which are a testament to the value of
Caris' comprehensive molecular profiling and the power of our
ever-expanding network of POA collaborations," said Caris EVP and
Chief Medical Officer George W. Sledge,
Jr., MD. "The diverse array of findings underscores the
critical role of comprehensive profiling in cancer care and the
power of large clinico-genomic datasets to enable the
identification of new biomarkers with clinical implications across
diverse tumor types, including lung, prostate and breast cancer.
Through extensive sequencing and data analysis efforts, we're
unlocking new avenues for tailored therapies to revolutionize
cancer treatment."
"Caris enables clinicians to make the best individualized
treatment choices for their patients, researchers to discover new
actionable targets and our biopharmaceutical partners to develop
the next breakthrough medicines," said Caris President David
Spetzler, MS, PhD, MBA. "In collaboration with leading
oncology experts in the POA, our clinicians and scientists leverage
vast real-world evidence from over 632,000 lifetime clinical cases,
including over 482,000 with matched molecular data and outcomes in
Caris' unique AI-driven platform, to unravel the complexities of
cancer. Together, we're revealing the intricacies of the molecular
and immune landscapes of tumors and how these impact clinical
outcomes, paving the way for personalized therapies and improved
patient outcomes."
Rapid Oral Presentations:
- Genomic and tumor microenvironment dynamics of brain
metastases in breast cancer. (Abstract Number: 1018)
Monday, June 3; 12:06 PM – 12:10 PM
CDT
- Clinical utility of transcriptomic signatures to identify
androgen receptor and neuroendocrine signaling in prostate
cancer. (Abstract Number: 5015)
Monday, June 3; 2:03 PM – 2:09 PM
CDT
Merit Award Poster:
- The molecular landscape of pembrolizumab and lenvatinib
treatment in endometrial cancer. (Abstract Number: 5612)
Monday, June 3; 9:00 AM – 12:00 PM
CDT
Other notable studies focus on key topics including molecularly
guided treatment strategies, predictors of therapeutic response and
novel prognostic biomarkers:
- The molecular landscape of PIWIL1 expression in
colorectal adenocarcinoma (CRC). (Abstract Number: 3546)
Saturday, June 1; 1:30 PM – 4:30 PM
CDT
- RNA expression-based hypoxia score as a prognostic and
predictive biomarker in hepatocellular carcinoma. (Abstract
Number: 4026)
Saturday, June 1; 1:30 PM – 4:30 PM
CDT
- Therapeutic strategy for targeting recurrent oncogenic
kinase gene fusions in prostate cancer. (Abstract Number:
5093)
Sunday, June 2; 9:00 AM – 12:00 PM
CDT
- Kinome reprogramming as a therapeutic opportunity in ESR1
fusion driven breast cancer but not in gynecologic cancers.
(Abstract Number: 1045)
Sunday, June 2; 9:00 AM – 12:00 PM
CDT
- Molecular and immunological characterization of androgen
receptor expression in different breast cancer subtypes.
(Abstract Number: 1114)
Sunday, June 2; 9:00 AM – 12:00 PM
CDT
- Characterization of TP53 mutations in actionable
driver-negative non-small cell lung cancer (NSCLC). (Abstract
Number: 8621)
Monday, June 3; 1:30 PM – 4:30 PM
CDT
- Association
of germline HSD3B1 (c.1100) genotype with
tumoral and clinical outcomes in breast and endometrial
cancers. (Abstract Number: 10587)
Monday, June 3; 1:30 PM – 4:30 PM
CDT
- Immunotherapy outcomes and profile in lung cancer brain
metastases. (Abstract Number: 8646)
Monday, June 3; 1:30 PM – 4:30 PM CDT
- Multidimensional analysis of B7 homolog 3 (B7-H3) RNA
expression in small-cell lung cancer (SCLC) molecular subtypes.
(Abstract Number: 8088)
Monday, June 3; 1:30 PM – 4:30 PM
CDT
Poster and abstract summaries highlighting the Caris research
presented at ASCO 2024 will be available onsite at Caris' Booth
28001. The full abstracts will be available on the Caris
website beginning on June
1st.
The POA includes 91 cancer centers, academic institutions,
research consortia and healthcare systems, including 43
NCI-designated cancer centers, collaborating to advance precision
oncology and biomarker-driven research. POA members work together
to establish and optimize standards of care for molecular testing
through innovative research focused on predictive and prognostic
markers that improve the clinical outcomes for cancer patients.
About Caris Life Sciences
Caris Life
Sciences® (Caris) is the
leading next-generation AI TechBio company and
precision medicine pioneer that is actively developing and
delivering innovative solutions to revolutionize healthcare and
improve the human condition. Through comprehensive molecular
profiling (Whole Exome and Whole Transcriptome
Sequencing) and the application of advanced AI and machine
learning algorithms, Caris has created the
large-scale, multi-modal database and computing capability needed
to analyze and unravel the molecular complexity of disease. This
convergence of sequencing power, big data and AI technologies
provides an unmatched platform to deliver the next generation of
precision medicine tools for early detection, diagnosis,
monitoring, therapy selection and drug development.
Headquartered in Irving, Texas,
Caris has offices in Phoenix, New
York, Cambridge (MA),
Tokyo, Japan and Basel, Switzerland. Caris or its distributor
partners provide services in the U.S., Europe, Asia
and other international markets. To learn more, please visit
CarisLifeSciences.com.
Caris Life Sciences Media Contact:
Lisa Burgner
corpcomm@carisls.com
214.294.5606
View original content to download
multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-showcase-extensive-research-highlighting-the-clinical-value-of-comprehensive-molecular-profiling-at-asco-2024-302144230.html
SOURCE Caris Life Sciences